In efforts to combine Bcl-2 inhibition with approved AML therapies, venetoclax was found to synergistically induce apoptosis when combined with cytarabine in AML cell lines and primary patient samples.84 In a phase Ib/II clinical trial (NCT02287233), untreated AML patients aged >60 years were enrolled and treated with venetoclax in 28-day cycles and was combined with LDAC subcutaneously on days 1 to 10.38 The ORR was 54%, with 26% achieving CR and 28% achieving CRi. Here, BCL2 is linked to acute myeloid leukemia.